Menu Close

Inside the tactical tug of war over the controversial Alzheimer’s drug

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled—and hinted at a lawsuit—over the decision to pay only for patients taking the drug in a clinical trial.

Generated by Feedzy